| Literature DB >> 34063673 |
Blanca De-la-Cruz-Torres1, Vanesa Abuín-Porras2, Emmanuel Navarro-Flores3, César Calvo-Lobo4, Carlos Romero-Morales2.
Abstract
OBJECTIVE: The aim was to analyze effects of a percutaneous neuromodulation (PNM) treatment on the radial nerve, regarding pain, functionality, electrophysiologic excitability, and morphology, in patients with chronic lateral epicondylalgia (LE).Entities:
Keywords: chronic pain; lateral epicondylalgia; neuromodulation; percutaneous nerve stimulation; radial nerve; rehabilitation; ultrasound
Year: 2021 PMID: 34063673 PMCID: PMC8125558 DOI: 10.3390/ijerph18094877
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1US-Guided PNM: (a) PES intervention in the radial nerve; (b) Ultrasound image of the intervention. B: brachialis muscle; BR: brachioradialis muscle, RN: radial nerve, H: humerus; and (c) ultrasound-guided invasive approach of the radial nerve.
Sociodemographic data and clinical features.
| Characteristic | Total Sample | Control Group | PNM Group | |
|---|---|---|---|---|
| Age (years) | 49.4 ± 7.6 | 49.4 ± 5.5 | 49.5 ± 9.5 | 0.979 |
| Weight (Kg) | 68.6 ± 12.13 | 66.83 ± 11.16 | 70.41 ± 13.2 | 0.482 |
| Height (cm) | 170.5 ± 9.6 | 170.00 ± 9.85 | 171.6 ± 8.7 | 0.808 |
| BMI (kg/m2) | 23.44 ± 2.5 | 22.98 ± 2.23 | 23.8 ± 2.80 | 0.392 |
| Gender (F/M) | 12 F/12 M | 6 F/6 M | 6 F/6 M | n/a |
| Use of the affected arm (R/L) | 24/0 | 12/0 | 12/0 | n/a |
| Hand dominance (R/L) | 24/0 | 12/0 | 12/0 | n/a |
| Duration of Symptoms (months) | 13.6 ± 9.10 | 12.4 ± 8.06 | 14.9 ± 10.2 | 0.513 |
Data given as mean ± SD. PRTEE: Patient-Rated Tennis Elbow Evaluation scores; CSA: cross-section area. * Between-groups statistical significance (one factor-ANOVA). p values (p < 0.05).
Clinical features, Patient-Rated Tennis Elbow Evaluation (PRTEE) scores, cross-section area (CSA) scores and chronaxie and accommodation index (AI) intrasubject effects.
| Intrasubject Effects | ||||
|---|---|---|---|---|
| Measure | PNM Group (n = 12) | Control Group (n = 12) | Time Value | Treatment X Time |
| NRS (point) | F (1, 22) = 102.47; | F (1, 22) = 105.36; | ||
| Baseline | 7.7 ± 0.9 | 7.6 ± 1.15 | ||
| Post-Treatment † | 1.7 ± 1.8 | 7.6 ± 1.0 | ||
| PRTEE (total score) | F (1, 22) = 40.28; | F (1, 22) = 54.73; | ||
| Baseline | 83.3 ± 22.4 | 75.6 ± 22.6 | ||
| Post-Treatment † | 38.6 ± 22.2 | 79.0 ± 25.2 | ||
| PRTEE (pain score) | F (1, 22) = 24.06; | F (1, 22) = 17.609; | ||
| Baseline | 28.5 ± 7.0 | 29.6 ± 6.7 | ||
| Post-Treatment † | 15.75 ± 7.8 | 28.6 ± 7.2 | ||
| PRTEE (functional subscale-specific activities) | F (1, 22) = 18.62; | F (1, 222) = 29.28 | ||
| Baseline | 30.9 ± 13.8 | 26.9 ± 13.0 | ||
| Post-Treatment † | 13.1 ± 10.7 | 28.9 ± 14.4 | ||
| PRTEE (functional subscale-usual activities) | F (1, 22) = 38.30; | F (1, 22) = 58.78 | ||
| Baseline | 23.0 ± 6.0 | 21.4 ± 7.8 | ||
| Post-Treatment † | 10.5 ± 7.3 | 22.7 ± 5.9 | ||
| CSA (mm2) | F (1, 22) = 42.06; | F (1, 22) = 39.60; | ||
| Baseline | 0.74 ± 0.13 | 0.69 ± 0.1 | ||
| Post-Treatment † | 0.57 ± 0.1 | 0.69 ± 0.1 | ||
| Chronaxie | F (1, 22) = 1.03; | F (1, 22) = 0.55; | ||
| Baseline | 0.70 ± 0.2 | 0.74 ± 0.2 | ||
| Post-Treatment † | 0.60 ± 0.2 | 0.72 ± 0.1 | ||
| AI | F (1, 22) = 15.88; | F (1, 22) = 22.59 | ||
| Baseline | 2.35 ± 0.5 | 2.45 ± 0.4 | ||
| Post-Treatment † | 3.11 ± 0.5 | 2.39 ± 0.5 | ||
Values are mean ± SD unless otherwise indicated. † Significant differences (p < 0.05) between PNM group and control group. Abbreviature: AI, accommodation index; CSA, cross-sectional area; NRS, numerical rating scale; ROM, range of motion.